Brincidofovir for prevention of cytomegalovirus (CMV) after allogeneic hematopoietic cell transplantation (HCT) in CMV-seropositive patients: A pandomized, double-blind, placebo-controlled, parallel-group phase 3 trial
Published in 2016 by
F. M. Marty,
D. J. Winston,
R. F. Chemaly,
M. J. Boeckh,
K. M. Mullane,
T. B. Shore,
G. A. Papanicolaou 
,
M. E. Morrison,
T. M. Brundage,
H. Mommeja-Marin
,
M. E. Morrison,
T. M. Brundage,
H. Mommeja-Marin
